Latest Breaking News On - Turning point pharmaceuticals - Page 1 : vimarsana.com

FDA approval of Bristol Myers Squibb’s Augtyro covers treatment of patients whose non-small cell lung cancer is driven by the rare ROS1 mutation. The molecule comes from BMS’s 2022 acquisition of Turning Point Therapeutics.

United statesWilliam blairMatt phippsNick botwoodRoche rozlytrekAmerican lung associationBristol myers squibbPoint pharmaceuticalsAmerican lungAmerican societyClinical oncologyTurning point pharmaceuticalsSan diego based turningWeight lossMedical devicesHealthcare innovation